The company is a spin-off from the Vrije Universiteit Brussel - Diabetes Research Center (VUB-DRC). The DRC is a leader in the biology of insulin-producing beta cells and its use as platform for novel methods in the diagnosis and treatment of diabetes. It has particular expertise in cell isolation and quality control, stem/precursor cell characterization and differentiation, preparation of standardized beta cell grafts and organization and funding of multi-center clinical trials in diabetes patients. DRC is an internationally recognized center of excellence in the field of diabetes. Beta-Cell’s technology platform is based on prior, current and future work at the DRC. It has acquired proprietary technology for a first product line, with BetaGRAFT® as a lead, and has an agreement on its first right of refusal on all diabetes related Intellectual Property (IP) generated at DRC. Recent developments have opened a second line in the field of beta cell regeneration, with BetaREG as a lead, and a third one in the field of drug screening and discovery, defined as BetaSCREEN.